Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108136
Title:
Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.
Authors:
Ghosh, Anna K; Dazzi, H; Thatcher, Nick; Moore, M
Abstract:
A phase-I/II study of recombinant interleukin 2 (rIL-2) was performed in 31 melanoma patients. The first dose of rIL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum tolerated single dose was 11 x 10(6) Cetus U/m2. Haematological and immunological data were available on 20 patients. Post-treatment response to rIL-2 therapy was evident from (i) a rapid depletion of peripheral blood lymphocytes (PBL) with a rebound at 4-7 days (2 times pre-treatment values); (ii) an increase in the number of IL-2 receptor-positive lymphocytes (4-15 times pre-treatment values); (iii) an increase in the number of "positive" patients with cytotoxic (anti-K562) peripheral blood mononuclear cells (PBMC) from 30% to 80%; (iv) amplified killing of K562 by positive patients in relation to pre-treatment values; and (v) the induction of PBMC cytotoxicity (in 45% of patients) against the NK-resistant, LAK-sensitive target, Mel I. Partial clinical responses to rIL-2 treatment were observed in 4 patients, but these were not reflected in the PBMC LAK activity or the other parameters examined.
Affiliation:
Cancer Research Campaign, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.
Citation:
Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. 1989, 43 (3):410-4 Int. J. Cancer
Journal:
International Journal of Cancer
Issue Date:
15-Mar-1989
URI:
http://hdl.handle.net/10541/108136
DOI:
10.1002/ijc.2910430311
PubMed ID:
2784419
Type:
Article
Language:
en
ISSN:
0020-7136
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorGhosh, Anna Ken
dc.contributor.authorDazzi, Hen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorMoore, Men
dc.date.accessioned2010-07-22T08:46:15Z-
dc.date.available2010-07-22T08:46:15Z-
dc.date.issued1989-03-15-
dc.identifier.citationLack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. 1989, 43 (3):410-4 Int. J. Canceren
dc.identifier.issn0020-7136-
dc.identifier.pmid2784419-
dc.identifier.doi10.1002/ijc.2910430311-
dc.identifier.urihttp://hdl.handle.net/10541/108136-
dc.description.abstractA phase-I/II study of recombinant interleukin 2 (rIL-2) was performed in 31 melanoma patients. The first dose of rIL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum tolerated single dose was 11 x 10(6) Cetus U/m2. Haematological and immunological data were available on 20 patients. Post-treatment response to rIL-2 therapy was evident from (i) a rapid depletion of peripheral blood lymphocytes (PBL) with a rebound at 4-7 days (2 times pre-treatment values); (ii) an increase in the number of IL-2 receptor-positive lymphocytes (4-15 times pre-treatment values); (iii) an increase in the number of "positive" patients with cytotoxic (anti-K562) peripheral blood mononuclear cells (PBMC) from 30% to 80%; (iv) amplified killing of K562 by positive patients in relation to pre-treatment values; and (v) the induction of PBMC cytotoxicity (in 45% of patients) against the NK-resistant, LAK-sensitive target, Mel I. Partial clinical responses to rIL-2 treatment were observed in 4 patients, but these were not reflected in the PBMC LAK activity or the other parameters examined.en
dc.language.isoenen
dc.subjectSkin Canceren
dc.subject.meshCytotoxicity, Immunologic-
dc.subject.meshDrug Evaluation-
dc.subject.meshHumans-
dc.subject.meshInterleukin-2-
dc.subject.meshKiller Cells, Natural-
dc.subject.meshLeukocyte Count-
dc.subject.meshLeukocytes, Mononuclear-
dc.subject.meshLymphocytes-
dc.subject.meshMelanoma-
dc.subject.meshPhenotype-
dc.subject.meshReceptors, Interleukin-2-
dc.subject.meshRecombinant Proteins-
dc.subject.meshSkin Neoplasms-
dc.titleLack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.en
dc.identifier.journalInternational Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.